BioNTech’s HER2 antibody-drug conjugate has beaten Roche’s Kadcyla in a phase 3 breast cancer trial, positioning the company’s partner Duality Biologics to seek approval for the candidate in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results